The UK National Institute for Health and Care Excellence (NICE) issued positive interventional procedures guidance for transcranial magnetic stimulation in fibromyalgia pain management. The guidance recommends NHS coverage subject to a cost-effectiveness review expected to complete in Q3 2026.
The decision was based on a systematic review of 18 randomized controlled trials enrolling roughly 1,100 fibromyalgia patients. Pooled results showed clinically meaningful pain reductions sustained at 12 weeks following motor cortex stimulation. Quality of life and sleep also improved.
Fibromyalgia affects roughly 2-4% of UK adults and has limited evidence-based treatment options beyond exercise, cognitive behavioral therapy, and a small number of medications. NICE specifically noted the absence of effective options for patients who cannot tolerate first-line pharmacotherapy as a factor in the recommendation.
If the cost-effectiveness review is favorable, NHS England would be expected to fund TMS for fibromyalgia at specialist pain centers beginning in late 2026. U.S. coverage for TMS in fibromyalgia remains rare and largely off-label.
Source
Reporting based on coverage from NICE. This article is editorial summary intended for general information; it is not medical advice.